001     126504
005     20240228140829.0
024 7 _ |a 10.1042/CS20140606
|2 doi
024 7 _ |a pmid:25602745
|2 pmid
024 7 _ |a 0009-9287
|2 ISSN
024 7 _ |a 0143-5221
|2 ISSN
024 7 _ |a 0301-0538
|2 ISSN
024 7 _ |a 1470-8736
|2 ISSN
024 7 _ |a altmetric:3848536
|2 altmetric
037 _ _ |a DKFZ-2017-02532
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Feng, Teng
|b 0
245 _ _ |a Smad7 regulates compensatory hepatocyte proliferation in damaged mouse liver and positively relates to better clinical outcome in human hepatocellular carcinoma.
260 _ _ |a London
|c 2015
|b Portland
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1523878965_1584
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Transforming growth factor β (TGF-β) is cytostatic towards damage-induced compensatory hepatocyte proliferation. This function is frequently lost during hepatocarcinogenesis, thereby switching the TGF-β role from tumour suppressor to tumour promoter. In the present study, we investigate Smad7 overexpression as a pathophysiological mechanism for cytostatic TGF-β inhibition in liver damage and hepatocellular carcinoma (HCC). Transgenic hepatocyte-specific Smad7 overexpression in damaged liver of fumarylacetoacetate hydrolase (FAH)-deficient mice increased compensatory proliferation of hepatocytes. Similarly, modulation of Smad7 expression changed the sensitivity of Huh7, FLC-4, HLE and HLF HCC cell lines for cytostatic TGF-β effects. In our cohort of 140 HCC patients, Smad7 transcripts were elevated in 41.4% of HCC samples as compared with adjacent tissue, with significant positive correlation to tumour size, whereas low Smad7 expression levels were significantly associated with worse clinical outcome. Univariate and multivariate analyses indicate Smad7 levels as an independent predictor for overall (P<0.001) and disease-free survival (P=0.0123). Delineating a mechanism for Smad7 transcriptional regulation in HCC, we identified cold-shock Y-box protein-1 (YB-1), a multifunctional transcription factor. YB-1 RNAi reduced TGF-β-induced and endogenous Smad7 expression in Huh7 and FLC-4 cells respectively. YB-1 and Smad7 mRNA expression levels correlated positively (P<0.0001). Furthermore, nuclear co-localization of Smad7 and YB-1 proteins was present in cancer cells of those patients. In summary, the present study provides a YB-1/Smad7-mediated mechanism that interferes with anti-proliferative/tumour-suppressive TGF-β actions in a subgroup of HCC cells that may facilitate aspects of tumour progression.
536 _ _ |a 317 - Translational cancer research (POF3-317)
|0 G:(DE-HGF)POF3-317
|c POF3-317
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Smad7 Protein
|2 NLM Chemicals
650 _ 7 |a Transforming Growth Factor beta
|2 NLM Chemicals
650 _ 7 |a Y-Box-Binding Protein 1
|2 NLM Chemicals
650 _ 7 |a YBX1 protein, human
|2 NLM Chemicals
700 1 _ |a Dzieran, Johanna
|b 1
700 1 _ |a Gu, Xing
|b 2
700 1 _ |a Marhenke, Silke
|b 3
700 1 _ |a Vogel, Arndt
|b 4
700 1 _ |a Machida, Keigo
|b 5
700 1 _ |a Weiss, Thomas S
|b 6
700 1 _ |a Ruemmele, Petra
|b 7
700 1 _ |a Kollmar, Otto
|b 8
700 1 _ |a Hoffmann, Patrick
|b 9
700 1 _ |a Grässer, Friedrich
|b 10
700 1 _ |a Allgayer, Heike
|0 P:(DE-He78)69067807288b48415ceb4abc43b9ad54
|b 11
|u dkfz
700 1 _ |a Fabian, Jasmin
|b 12
700 1 _ |a Weng, Hong Lei
|b 13
700 1 _ |a Teufel, Andreas
|b 14
700 1 _ |a Maass, Thorsten
|b 15
700 1 _ |a Meyer, Christoph
|b 16
700 1 _ |a Lehmann, Ulrich
|b 17
700 1 _ |a Zhu, Cheng
|b 18
700 1 _ |a Mertens, Peter R
|b 19
700 1 _ |a Gao, Chun Fang
|b 20
700 1 _ |a Dooley, Steven
|b 21
700 1 _ |a Meindl-Beinker, Nadja M
|b 22
773 _ _ |a 10.1042/CS20140606
|g Vol. 128, no. 11, p. 761 - 774
|0 PERI:(DE-600)1484392-4
|n 11
|p 761 - 774
|t Clinical science
|v 128
|y 2015
|x 1470-8736
909 C O |o oai:inrepo02.dkfz.de:126504
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)69067807288b48415ceb4abc43b9ad54
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-317
|2 G:(DE-HGF)POF3-300
|v Translational cancer research
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CLIN SCI : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)G360-20160331
|k G360
|l KKE Molekulare Onkologie solider Tumoren
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)G360-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21